Adding Compound Kushen Injection (CKI), a traditional Chinese medicine, to chemotherapy treatment enhanced treatment response and reduced side effects in advanced colorectal cancer patients.
Meta-Analysis Colorectal Cancer Ku Shen
This study systematically collected data from a myriad of sources including, but not limited to, PubMed, the Cochrane Library, and ClinicalTrials.gov up to April 20, 2024. An assessment tool, ROB2, was used to measure the quality of the included trials, while data analysis was done using Stata 16. Publication bias was evaluated with the funnel plot and Egger's test. To calculate the final required sample size in this meta-analysis and verify whether the results presented a stable conclusion, trial sequential analysis was used.
The data collected from these sixteen trials, consisting of 1378 patients showcased that when compared to chemotherapy alone, the combination of CKI and chemotherapy resulted in improved response rates and enhancement of the patient's performance status. Furthermore, this combination therapy was associated with fewer adverse reactions like leukopenia, thrombocytopenia, gastrointestinal reactions, and liver damage. Patients also exhibited high CD4 ratios and comparatively low CD8 T cell ratios. A subgroup analysis further demonstrated that the response rates improved significantly when CKI was combined with specific chemotherapy regimens. Overall, this data strongly suggests that the addition of CKI to chemotherapy provided statistically significant and clinically relevant improvements in treatment response rates, patient wellbeing, reduction in adverse reactions, and enhanced immune function.
View Article